Lenabasum in Cystic Fibrosis
Details
- Therapeutic approach
- Anti-Inflammatory
- Trial status
- Closed with results Participating Centres
- Trials Tracker ID
- TT001871
- Last updated
- 03/09/2019
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Study detailsThis study is designed to evaluate the effectiveness and safety of lenabasum (JBT-101) in people with CF who have had pulmonary exacerbations. Lenabasum (JBT-101) is an oral medication that is aimed at reducing inflammation. It is thought to help the body increase production of anti-inflammatory molecules while reducing production of molecules that increase inflammation. Reduction of inflammation helps prevent permanent tissue damage in the lungs that happens when CF patients have pulmonary exacerbations. For study participants this study includes 6 months of study treatment with a 1 month follow up period. Study participants may remain on their current CF treatments
- Phase
- Phase 2
- Recruitment target
- 415
- CF sponsor
- Corbus Pharmaceuticals Inc.
- CF sponsor type
- Commercial
Who can take part?
- Age range
- 12 years and older
- Including people
12 Years and older
Over 40 kg
Able to perform pulmonary function tests- Excluding people
Severe or unstable CF at screening or visit one
Actively listed on an organ transplant list or have had an organ transplant other than corneal transplant